Skip to main content

Jamaine Davis, Ph.D.

  • Assistant Professor of Biochemistry and Cancer Biology, Meharry Medical College

Jamaine Davis, Ph.D.

  • Assistant Professor of Biochemistry and Cancer Biology, Meharry Medical College

jdavis@mmc.edu

Research Program

Have any questions? Contact Us 1-877-936-8422 for more information

Amos M. Sakwe, Ph.D., M.S.C.I.

  • Associate Professor of Biochemistry and Cancer Biology, Meharry Medical College

Phone

(615) 327-6064

Email

asakwe@mmc.edu
School of Graduate Studies and Research
West Basic Science Bldg, Room 2141B/3108
Meharry Medical College
Nashville, TN 37208

Amos M. Sakwe, Ph.D., M.S.C.I.

  • Associate Professor of Biochemistry and Cancer Biology, Meharry Medical College

(615) 327-6064

asakwe@mmc.edu

School of Graduate Studies and Research
West Basic Science Bldg, Room 2141B/3108
Meharry Medical College
Nashville, TN 37208

Research Program

Have any questions? Contact Us 1-877-936-8422 for more information

 

VICC Seminar Series

This trial uses fluid measurements of the arm and MRI to determine biomarkers of lymphatic dysfunction in patients with breast cancer. Studying the lymphatic system (the part of your body that helps to process and clear waste products) in different ways will help doctors understand more about lymphedema (excess fluid after lymph nodes are removed) and help with prevention and management of lymphedema in patients with breast cancer.
This phase III trial compares the effect of an accelerated schedule of bleomycin sulfate, etoposide phosphate, and cisplatin (BEP) chemotherapy to the standard schedule of BEP chemotherapy for the treatment of patients with intermediate or poor-risk germ cell tumors that have spread to other places in the body (metastatic). Drugs used in chemotherapy, such as bleomycin sulfate, etoposide phosphate, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BEP chemotherapy on a faster, or accelerated schedule may work better with fewer side effects in treating patients with intermediate or poor-risk metastatic germ cell tumors compared to the standard schedule.
Subscribe to